Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc.
Company typePublic
AMEX: LCTXTASE: LCTX
IndustryBiotechnology, regenerative medicine
Founded1990
HeadquartersCarlsbad, California
Key people
Brian Culley, CEO

Jill Howe, CFO

George A. Samuel III, General Counsel & Corporate Strategy
Websitelineagecell.com

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities.[1] With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer.[2]

Lineage’s clinical and preclinical programs are in markets with billion dollar opportunities and include five allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, which is being developed under a worldwide collaboration with Genentech, a member of the Roche Group;[3][4] (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries;[5] (iii) VAC2, an allogeneic dendritic cell therapy produced from Lineage's VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer;[6][7] (iv) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy;[8][9] and (v) PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage.[10][11]

  1. ^ "Company". Lineage Cell Therapeutics. Retrieved 2020-12-14.
  2. ^ "Cell Therapy". Lineage Cell Therapeutics. Retrieved 2020-12-14.
  3. ^ "Lineage Establishes Exclusive Worldwide Collaboration With Genentech for the Development and Commercialization of OpRegen® RPE Cell Therapy for the Treatment of Ocular Disorders". www.businesswire.com. 2021-12-20. Retrieved 2022-11-16.
  4. ^ "Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration – Full Text View – ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2020-12-14.
  5. ^ Lineage Cell Therapeutics, Inc. (2020-07-14). "A Phase 1/2a Dose Escalation Study of AST-OPC1 in Subjects With Subacute Cervical Spinal Cord Injury". {{cite journal}}: Cite journal requires |journal= (help)
  6. ^ Cancer Research UK (2020-11-10). "A Cancer Research UK Phase I Trial of AST-VAC2 (Allogeneic Dendritic Cell Vaccine) Administered Weekly Via Intradermal Injection in Patients With Non-small Cell Lung Cancer (NSCLC) in the Advanced and Adjuvant Settings". {{cite journal}}: Cite journal requires |journal= (help)
  7. ^ "VAC2". Lineage Cell Therapeutics. Retrieved 2022-11-16.
  8. ^ "Lineage Announces Pipeline Expansion to Include Auditory Neuronal Cell Therapy for Treatment of Hearing Loss". BioSpace. Retrieved 2022-11-16.
  9. ^ "Pipeline". Lineage Cell Therapeutics. Retrieved 2022-11-16.
  10. ^ "Lineage Announces a Fifth Cell Therapy Program: Allogeneic Photoreceptor Transplants for the Treatment of Diseases Which May Lead to Blindness". www.businesswire.com. 2022-04-25. Retrieved 2022-11-16.
  11. ^ "Pipeline". Lineage Cell Therapeutics. Retrieved 2022-11-16.